The relevance of regional lymph node (LN) assessment to quantify the metastatic spread of cancer is well recognized in veterinary oncology. Evaluation of LNs is critical for tumour staging. However, sampling the correct LN may not be possible without sentinel lymph node (SLN) mapping. Methods for diagnostic imaging and intraoperative detection of SLNs are well established in human medicine, in particular, the combination of lymphoscintigraphy and intraoperative application of blue dyes. Nevertheless, alternative imaging techniques are available and have gained increasing interest. Successful implementation of these techniques in dogs have been reported in both clinical and experimental studies. This review aims to provide an overview of SLN mapping techniques in human and veterinary medicine. While the majority of sarcomas disseminate by vascular invasion, carcinomas and round cell tumours primarily spread through the lymphatic system and initially metastasize to the regional lymph nodes (LNs, Figure 1A 
The relevance of regional lymph node (LN) assessment to quantify the metastatic spread of cancer is well recognized in veterinary oncology. Evaluation of LNs is critical for tumour staging. However, sampling the correct LN may not be possible without sentinel lymph node (SLN) mapping. Methods for diagnostic imaging and intraoperative detection of SLNs are well established in human medicine, in particular, the combination of lymphoscintigraphy and intraoperative application of blue dyes. Nevertheless, alternative imaging techniques are available and have gained increasing interest. Successful implementation of these techniques in dogs have been reported in both clinical and experimental studies. This review aims to provide an overview of SLN mapping techniques in human and veterinary medicine.
K E Y W O R D S
comparative oncology, lymph node biopsy, lymphatic metastasis, sentinel lymph node mapping, surgical oncology
| INTRODUCTION
According to the literature, the combined incidence of malignant and benign tumours in dogs varies between 310 to 9584 and 760 to 1130 per 100 000 dogs per year, respectively. 1, 2 The most common malignant lesions arise from the skin and from the mammary glands in female dogs. 2 Tumour staging, which refers to determining the extent the cancer has spread, is critical to predict the prognosis and guide the clinician in treatment decision-making. Metastatic spread of cancer is one of the major causes of death in certain tumour types. 3, 4 Hematogenous and lymphatic passage of tumour cells are the 2 major routes of dissemination that should be considered when staging any cancer.
While the majority of sarcomas disseminate by vascular invasion, carcinomas and round cell tumours primarily spread through the lymphatic system and initially metastasize to the regional lymph nodes (LNs, Figure 1A ) 5 . The sentinel lymph node (SLN) is defined as the first LN within the lymphatic basin that drains the primary tumour and so examination of the SLN is indicated to detect the presence of locoregional nodal metastasis ( Figure 1B ). 6 The SLN may be the regional LN anticipated to be responsible for tumour drainage, but LNs at unpredictable anatomical locations might also function as the SLN. 7 For accurate tumour staging, palpation and sampling the regional LN by fine needle aspiration (FNA) or biopsy has been traditionally recommended in veterinary medicine. 8 However, in up to 60% of cases the inability to assess LN by palpation or ultrasound means malignant cells within SLN may not be sampled. 9 The diagnosis of a metastatic LN may be missed in more than 85% of cases if LN assessment is performed by palpation alone. 9 If a normal to mildly enlarged LN is considered free of metastasis, the sensitivity and specificity for palpation was reported to be 60% and 72%, respectively. 10 This is low if compared to the results of fine needle aspirates and histology of core biopsies which have a confirmed sensitivity and specificity of 100% and 96% and 64% and 94%, respectively. 10 Thus, accurate methods for detecting the SLNs may provide crucial information on tumour prognosis and may guide the clinician on treatment selection. 6 In recent decades, human research has made strong efforts to develop new methods and refine existing imaging techniques for the better detection of SLNs. 11 Sampling of SLNs offers a less invasive approach than radical regional lymphadenectomy, minimizes anaesthesia time and reduces tissue trauma and postoperative morbidity. 12, 13 For these reasons SLN mapping has successfully been established in human oncology, becoming an integral part of treatment decision-making and prognosis of certain malignancies. The aim of this review is to describe the most common techniques for SLN mapping both in people and in dogs. This review will discuss advantages and disadvantages of the available techniques for veterinary medicine and evaluate whether the current data is sufficient to recommend a technique as a safe and accurate method in small animal medicine. New imaging techniques for SLN mapping, applied in canine and feline models of human medicine, will be described to give some perspective on future application modalities in small animals.
| HISTORY OF SENTINEL LYMPH NODE MAPPING
The importance of the lymphatic system in the pathogenesis of tumour spreading was noticed more than a century ago when scientists started to investigate the functions of the lymphatic system. In the late 19th century, the German pathologist Rudolf L. K. Virchow described the role of LNs in filtering lymph and serving as a major barrier for cancer cells, 36, 37 assuming that the regional LNs were the first site to be affected by metastases. Therefore, it seemed reasonable to radically dissect the tumour and surrounding tissue including the regional LNs to achieve cure. This new concept was proposed by
Halstead who proved his theory in women suffering from breast cancer. 38 Radical surgical resections remained the treatment of choice for certain tumours until the mid-20th century when preclinical studies investigated the metastatic spread of carcinomas. Studies in dogs and rabbits showed that cancer cells spread in an orderly way through the lymphatic system demonstrating that metastases in LNs below the first LN were only detected if advanced metastatic lesions were present in the first LN. 39 The concept of SLN was first introduced by Gould et al in 1960 to describe LNs at a certain anatomical location that were presumed to drain cancerous parotid glands in people. 40 Radical neck or local gland dissection was selected based on the results of intraoperative pathologic evaluation of the LN termed "sentinel" for the first time. 40 Twenty years later Cabanas published the use of radiographic lymphography to image the lymph vessels and SLNs of men with penile cancer. 14 One of his conclusions was that SLNs were the first to be affected by metastasis. Biopsies of other LNs were not recommended if the SLN was free from metastatic disease. 14 Morton et al made a milestone for surgical oncology in the 1990s by describing a technique for intraoperative SLN mapping.
Blue dye was injected intradermally to stain draining lymph tracts and SLNs in people with cutaneous melanoma. 6 The next evolutionary step was to use a similar approach with scintigraphy. Although scintigraphic examination of the LNs had been performed since 1977, 6 it was only in 1993 when new portable gamma probes were available, that surgeons were able to detect radioactive uptake in SLN intraoperatively. 41, 42 Although the combination of these 2 techniques offered excellent results, several other modalities were studied for After injection, the contrast is drained towards the SLN via the lymphatic system. 9, 53 Taking serial radiographs within minutes after injection allows the delineation of these lymph vessels and SLNs.
9,29
The SLNs stay radiopaque for several days to months until the contrast is cleared from the lymphatic system. 25, 29 The contrast agents can also be injected directly into the tumour tissue, although it is not recommended because of the risk of capsular damage and subsequent tumour cell seeding. of mammary glands in healthy cats showed minor temporary swelling and 9.7% (3/31) inflammation after intramammary and subareolar contrast injection. 52 Severe complications such as allergic reactions or pulmonary embolism are reported in people but have not been observed in small animals to date.
The major advantages of radiographic lymphography are the general availability of the equipment, the non-invasive procedure 9,53 and simple technique 8 making it feasible for clinical practice. Nevertheless, the high rate of minor complications should be considered when using radiographic lymphography for SLN mapping. 29 
| COMPUTED TOMOGRAPHY LYMPHOGRAPHY
The main rationale for CT-lymphography was to develop a contrastbased technique that accurately displayed the anatomical location of the SLNs and the details of the surrounding tissue ( Figure 2 Recently, four veterinary studies proved the successful implementation of CT-lymphography in clinical canine patients with mammary cancer, 33 anal gland sac cancer 34 and tumours of various sites, 35, 107 respectively. The 4 studies used comparable CT imaging protocols including a pre-contrast CT study and sequential postcontrast images displayed in a soft tissue window, starting scanning within 1 minute after the injection. The contrast-filled afferent lymph vessels could be followed to 1 or more SLNs. [33] [34] [35] 107 In a pilot study including 18 dogs with variable tumours on the head, indirect CT-lymphography was successful in identifying the SLN in 16 cases (89%) with 2 patients having more than 1 SLN (13%). 35 Different LN opacification patterns were described by Soultani et al and SLN uptake was compared to their histopathological appearance: (1) a rather homogenous enhancement due to uniform distribution of contrast agent, (2) a heterogenous pattern with either a patchy distribution, opacification of the periphery of the SLN only or opacification of single areas and (3) a missing contrast uptake into the SLN. 33 While a homogenous contrast distribution was observed in SLNs free from metastases, a heterogenous pattern was associated with metastases. In 2 out of 33 dogs (including 22 bilateral tumours) no contrast uptake in the SLNs was visible despite the afferent lymphatics being delineated. Both SLNs contained metastases suggesting a discontinuance in the lymphatic flow due to metastatic obstruction. Likewise, a low Houndsfield unit in the centre of the SLN had a high sensitivity and specificity for SLN metastases. The authors concluded that CT lymphography is not only suitable for the detection of the SLNs, but may be a helpful tool to predict the presence of nodal metastasis. 33 Subsequently, Brissot and Edery used CT-lymphography to localize the SLN in cancer-bearing canine patients. 9 However, they did not specify how many patients received a CT-lymphography scan and how specific CT-lymphography was compared to other techniques. 9 Apart from these studies in cancer patients and human trials in healthy dogs, 15 The concept of MR-lymphography is the same as described for CT and radiographic lymphography. After a peritumoral interstitial infiltration, the contrast medium is taken up into the lymphatic vessels and transported to the SLN. MR-lymphography can identify contrast- showing that MR-lymphography may become an alternative to SLN biopsies. 62 Studies from veterinary medicine investigating the usefulness of MR-lymphography in animals are currently not available.
| CONTRAST-ENHANCED ULTRASOUND
CEUS is a popular technique in human medicine and is becoming increasingly common in veterinary medicine. It is mainly used to examine the blood flow and tissue perfusion of abdominal organs like the liver, spleen, pancreas or kidneys. 63 For these indications CEUS was considered to be safe and cost-effective in both humans 53 and small animals. 63, 64 Due to the problem that conventional ultrasound cannot accurately detect SLNs because of the inability to visualize afferent lymphatics, it seemed reasonable to investigate the application of CEUS for SLN mapping. To make the lymph vessels visible, sonographic contrast agents, consisting of small gas-filled microbubbles trapped in a lipid shell, are injected into the peritumoral tissue. [65] [66] [67] The high affinity of the lipid contrast to the lymphatic system means it enters the lymphatics within seconds 67 and drains to the SLNs within a few minutes, depending on the distance between the injection site and the SLN. 26, 65, 67 Enhanced by grey-scale or Doppler ultrasound they start oscillating thereby reflecting a signal several times higher than that of body tissue. 68 The technique has only been used preclinically, tested in proofof-concept studies mainly in pigs, 67 ,69 dogs 26,65-67, 70 and rabbits. 67 The first human trials were performed in breast cancer patients and 
| SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY AND POSITRON EMISSION TOMOGRAPHY
Sentinel node research using radioisotopes combined with SPECT/ CT, PET/CT or PET/MRI is evolving. SPECT/CT combines the advantages of preoperative scintigraphy with those of CT-lymphography allowing a highly accurate anatomical mapping of the lymphatic system 18 while PET/CT exploits metabolic characteristics of malignant cells to identify metastatic tumour tissue. 19 The latter technique has the potential to detect both regional LN metastases and distant organ spread; identifying patients requiring lymphadenectomy or a resection of metastases. 20 PET/CT, however, is not yet sensitive enough for the detection of micrometastases as confirmed by histologic examinations of SLNs. 19 Furthermore, SPECT/CT, PET/CT or PET/MRI is only possible in limited specialized facilities.
| LYMPHOSCINTIGRAPHY
The use of radioactive tracers for SLN mapping is a standard procedure in human cancer therapy, in particular, those with breast cancer or melanoma. 21 Radio-guided SLN mapping includes preoperative planar imaging and the intraoperative application of a hand-held gamma probe.
The radiotracers typically used are technetium-99m (Tc-99m) labelled colloids. 7, [73] [74] [75] SLNs, 34 were detected by the pre-and intraoperative lymphoscintigraphy, whereas only 27 SLNs were stained by patent blue dye. 77 A combination of using radioisotopes and methylene blue dye in dogs was reported in 2014. In 19 patients, 18 SLNs were detected by preoperative lymphoscintigraphy, 19 SLNs were found by the intraoperative use of a gamma probe and 18 were blue stained. 7 In healthy dogs, the feasibility of scintigraphy for SLN mapping has been confirmed by studies investigating the drainage of the prostate and mammary glands and pulmonary and thoracic tissue. [73] [74] [75] 78 Despite the popularity and high detection rates achieved with radio-guided SLN mapping in humans, its use is restricted due to radioactive materials. Permission is only granted at accredited institutions because of the increased safety precautions surrounding the application and disposal of the radiopharmaceuticals. Only few veterinary clinics, therefore, have access to radioactive tracers and the associated expensive equipment. Although the exposure of personnel sponding SLNs are stained blue and can be visualized if exposed or directly beneath the skin. 7 In human medicine the sole use of blue dye for SLN mapping has shown to be inferior in terms of the identification rate of SLNs (83%-85%) compared to radio-guided SLN identification alone (89.2%-94%) or combined methods (92%-99%) as reported in 2 systematic reviews. 21, 79 "Hot" and blue-stained nodes are more likely to be the first tier LN compared to those only "hot" and not blue. 80 Consequently, dyes are still recommended as an additional tool to provide a visual guide of SLNs labelled by radioactive tracers. 21 Similar conclusions were drawn for cancer bearing dogs by Balogh et al who reported the lack of sensitivity for blue dye only, and recommended the dual application of blue dye plus TC-99m. 77 However, in a recent study a sensitivity of 89.5% and a specificity of 100% were reported in dogs with mammary cancer after patent blue dye injection and removal of the entire mammary lymphatic chain. 32 Likewise, Worley provided evidence for a successful application of SLN mapping with blue dye and radioisotopes 7 while Brissot and Edery evaluated blue dye and radiographic lymphography in cancer bearing dogs. The latter observed an agreement of SLNs identified by either technique in 22/26 cases (84.6%). 9 Methylene blue dye was also used in several veterinary studies investigating the lymphatic drainage of healthy dogs and cats confirming its applicability.
81-83
SLN mapping with blue dyes is a cost-effective and simple technique. A study investigating the learning curve of SLN mapping with methylene blue in women with breast cancer considered 22 procedures to be sufficient to get familiar with the technique if performed by a surgeon in training. 84 From experience in human medicine, it is known that blue dyes are responsible for allergic reactions including erythema, urticarial and signs of anaphylaxis in approximately 0.4% cases. 80, 85 In rare cases, local skin necrosis is also described after blue dye injection. Such complications have not been reported in canine patients although the number of dogs in veterinary studies is very low compared to human trials. 7, 9 To overcome these problems, the usage of hemosiderin from autologous blood was described recently to stain the SLNs in 6 experimental dogs. It was used in combination with radioisotope labelling in 1 group and was compared to a group receiving patent blue dye and a radiocolloid. It was reported that hemosiderin stained the SLNs brown and was as useful as patent blue dye for SLN identification with no adverse reactions observed. 86 The safety and feasibility of using hemosiderin in humans has subsequently been reported. 87 
| NEAR-INFRARED IMAGING
NIR for SLN mapping is a rapidly developing field in human oncology.
It offers the opportunity of optical image-guided surgery to provide real time visualization of lymph vessels and SLNs. 22, 88 The nearinfrared light spectrum has a wavelength of 700 to 900 nm which are invisible to the human eye. 89 NIR imaging systems emit excitation light in the low near-infrared spectrum that gets absorbed by the fluorescent agent and shifted to a lower wavelength. The emitted light can be detected by an NIR camera device and translated to a real-time video displayed on a screen (Figures 5 and 6 ). 89, 90 In contrast to visible light, light of the near-infrared spectrum is hardly absorbed by body tissue which allows a tissue penetration up to a few centimetres, making NIR suitable for transcutaneous identification of SLNs in people and animals ( Figure 6 ). [88] [89] [90] [91] Several camera systems and fluorescent agents are currently available for clinical application. The most frequently used dye is Indocyanine Green (ICG) which was approved for clinical use (Food and Drug Administration) in 1959. 89 In human medicine, the technique is frequently used in patients with breast cancer 22, 91, 92 and melanoma 93 with reported detection rates comparable to that of lymphoscintigraphy. 88, 93 Nevertheless, there are several studies suggesting a slightly higher SLN detection rate with NIR than with conventional methods 22, 92, 93 which may be explained by the smaller particle size of fluorescent agents facilitating a faster spill into secondary LNs. 93 NIR for SLN mapping has also been adopted in minimally invasive surgery due to the availability and successful use of endoscopic and robotic-assisted NIR imaging systems. 45, 94 The creation of intravenously applied tumour-specific targeting dyes has also generated much interest. These dyes aim to demarcate the tumour's margins during the surgery to enable en bloc tumour resection with clean margins of excision. [95] [96] [97] [98] [99] This new approach of oncologic surgery was tested in animal models before applied clinically in humans, and so several results of such proof-of-concept-studies in canine are already available.
In 2006, a feasibility study in healthy dogs proved the applicability of NIR for SLN and lymph vessel visualization after intradermal injection. 83 Further studies in healthy experimental dogs were performed to assess a submucosal gastric injection of ICG 23, 100 and the intraprostatic injection of a radiolabeled fluorescent agent 94 for SLN mapping. The near-infrared light spectrum is invisible to the human eye and does not alter the appearance of the operation field which makes the technique easier to learn. 88 Simultaneously, due to visibility of the lymph vessels, NIR offers the opportunity to specifically identify the SLN within the first tier of the LN basin. 22, 88 No major complications have been reported in canine studies 95, 103 and NIR is considered as being a safe, simple and cost-effective technique in humans. 22, 46, 91 Disadvantages of NIR include the low depth of penetration that is limited to a few millimetres to centimetres 89 and the short time of tracer retention in the lymphatic system. 23 
| CONCLUSION
In human medicine it had been shown that for certain tumours the SLN status is crucial to predict prognosis and help to guide in the treatment. 105 Performing biopsies based on SLN mapping is considered standard of care for melanoma and breast cancer in people. 21 Intraoperative guidance of the surgeon towards these SLN has been shown to be an indispensable tool for increasing the detection rates, shortening anaes- As in human medicine, or perhaps more so, in veterinary medicine the application of simple and inexpensive, but accurate and safe CT-lymphography may be a preoperative mapping technique with future relevance for veterinary practitioners. CT is widely available and the application of contrast media is simple, quick and safe. 25, 52, 55 In contrast to radiographic lymphography, it offers detailed anatomical information. However, both techniques should be combined with an intraoperative detection procedure.
Real-time intraoperative guidance provided by NIR has a high sensitivity and safety profile, it is less expensive and less complicated compared to scintigraphy. 22 
